Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

Dick De Zeeuw; Giuseppe Remuzzi; Hans Henrik Parving; William F. Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E. Cooper; William E. Mitch; Barry M. Brenner

doi:10.1161/01.CIR.0000139860.33974.28

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

Dick De Zeeuw, Giuseppe Remuzzi, Hans Henrik Parving, William F. Keane, Zhongxin Zhang, Shahnaz Shahinfar, Steve Snapinn, Mark E. Cooper, William E. Mitch, Barry M. Brenner

Istituto di Ricerche Farmacologiche "Mario Negri"

Research output: Contribution to journal › Article

Abstract

Background-Albuminuria is an established risk marker for both cardiovascular and renal outcomes. Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention. Methods and Results-We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria. Patients with high baseline albuminuria (≥3 g/g creatinine) had a 1.92-fold (95% CI, 1.54 to 2.38) higher risk for the cardiovascular end point and a 2.70-fold (95% CI, 1.94 to 3.75) higher risk for heart failure compared with patients with low albuminuria (

Original language	English
Pages (from-to)	921-927
Number of pages	7
Journal	Circulation
Volume	110
Issue number	8
DOIs	https://doi.org/10.1161/01.CIR.0000139860.33974.28
Publication status	Published - Aug 24 2004

Keywords

Albuminuria
Angiotensin
Cardiovascular disease
Diabetes
Proteinuria

ASJC Scopus subject areas

Physiology
Cardiology and Cardiovascular Medicine

Access to Document

10.1161/01.CIR.0000139860.33974.28

Fingerprint Dive into the research topics of 'Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy'. Together they form a unique fingerprint.

Cite this

De Zeeuw, D., Remuzzi, G., Parving, H. H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004). Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation, 110(8), 921-927. https://doi.org/10.1161/01.CIR.0000139860.33974.28

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. / De Zeeuw, Dick; Remuzzi, Giuseppe; Parving, Hans Henrik; Keane, William F.; Zhang, Zhongxin; Shahinfar, Shahnaz; Snapinn, Steve; Cooper, Mark E.; Mitch, William E.; Brenner, Barry M.

In: Circulation, Vol. 110, No. 8, 24.08.2004, p. 921-927.

Research output: Contribution to journal › Article

@article{9d494dd140a14ba481da9d3ebf073299,

title = "Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy",

abstract = "Background-Albuminuria is an established risk marker for both cardiovascular and renal outcomes. Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention. Methods and Results-We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria. Patients with high baseline albuminuria (≥3 g/g creatinine) had a 1.92-fold (95% CI, 1.54 to 2.38) higher risk for the cardiovascular end point and a 2.70-fold (95% CI, 1.94 to 3.75) higher risk for heart failure compared with patients with low albuminuria (",

keywords = "Albuminuria, Angiotensin, Cardiovascular disease, Diabetes, Proteinuria",

author = "{De Zeeuw}, Dick and Giuseppe Remuzzi and Parving, {Hans Henrik} and Keane, {William F.} and Zhongxin Zhang and Shahnaz Shahinfar and Steve Snapinn and Cooper, {Mark E.} and Mitch, {William E.} and Brenner, {Barry M.}",

year = "2004",

month = aug,

day = "24",

doi = "10.1161/01.CIR.0000139860.33974.28",

language = "English",

volume = "110",

pages = "921--927",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

TY - JOUR

T1 - Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

AU - De Zeeuw, Dick

AU - Remuzzi, Giuseppe

AU - Parving, Hans Henrik

AU - Keane, William F.

AU - Zhang, Zhongxin

AU - Shahinfar, Shahnaz

AU - Snapinn, Steve

AU - Cooper, Mark E.

AU - Mitch, William E.

AU - Brenner, Barry M.

PY - 2004/8/24

Y1 - 2004/8/24

N2 - Background-Albuminuria is an established risk marker for both cardiovascular and renal outcomes. Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention. Methods and Results-We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria. Patients with high baseline albuminuria (≥3 g/g creatinine) had a 1.92-fold (95% CI, 1.54 to 2.38) higher risk for the cardiovascular end point and a 2.70-fold (95% CI, 1.94 to 3.75) higher risk for heart failure compared with patients with low albuminuria (

AB - Background-Albuminuria is an established risk marker for both cardiovascular and renal outcomes. Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention. Methods and Results-We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria. Patients with high baseline albuminuria (≥3 g/g creatinine) had a 1.92-fold (95% CI, 1.54 to 2.38) higher risk for the cardiovascular end point and a 2.70-fold (95% CI, 1.94 to 3.75) higher risk for heart failure compared with patients with low albuminuria (

KW - Albuminuria

KW - Angiotensin

KW - Cardiovascular disease

KW - Diabetes

KW - Proteinuria

UR - http://www.scopus.com/inward/record.url?scp=4344621497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344621497&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000139860.33974.28

DO - 10.1161/01.CIR.0000139860.33974.28

M3 - Article

C2 - 15302780

AN - SCOPUS:4344621497

VL - 110

SP - 921

EP - 927

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 8

ER -